Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Short Interest Up 20,081.7% in June

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) was the target of a significant increase in short interest in the month of June. As of June 30th, there was short interest totaling 158,023 shares, an increase of 20,081.7% from the June 15th total of 783 shares. Approximately 0.2% of the shares of the stock are sold short. Based on an average trading volume of 30,391 shares, the days-to-cover ratio is currently 5.2 days.

Ascentage Pharma Group International Stock Up 5.7%

Shares of AAPG stock traded up $1.07 during trading hours on Friday, reaching $19.97. 3,586 shares of the stock were exchanged, compared to its average volume of 19,701. Ascentage Pharma Group International has a 12-month low of $16.36 and a 12-month high of $48.45. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.79 and a quick ratio of 1.77. The company’s 50-day moving average price is $18.99 and its 200-day moving average price is $22.95.

Analysts Set New Price Targets

AAPG has been the subject of several research analyst reports. Raymond James Financial reaffirmed a “buy” rating on shares of Ascentage Pharma Group International in a research note on Wednesday, June 10th. China Intl Cap raised shares of Ascentage Pharma Group International to a “strong-buy” rating in a report on Monday, April 6th. B. Riley Financial started coverage on Ascentage Pharma Group International in a research report on Wednesday, June 10th. They set a “buy” rating and a $45.00 price objective for the company. BTIG Research reaffirmed a “buy” rating and issued a $48.00 target price on shares of Ascentage Pharma Group International in a report on Monday, June 15th. Finally, Deutsche Bank Aktiengesellschaft assumed coverage on Ascentage Pharma Group International in a research report on Friday, April 24th. They issued a “buy” rating and a $40.00 target price on the stock. Two analysts have rated the stock with a Strong Buy rating and eight have issued a Buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $46.43.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in AAPG. Hsbc Holdings PLC purchased a new position in Ascentage Pharma Group International during the 2nd quarter valued at about $391,000. UBS Group AG lifted its position in shares of Ascentage Pharma Group International by 149.4% in the 3rd quarter. UBS Group AG now owns 18,345 shares of the company’s stock worth $716,000 after purchasing an additional 10,988 shares during the period. XY Capital Ltd lifted its position in shares of Ascentage Pharma Group International by 224.2% in the 3rd quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock worth $707,000 after purchasing an additional 12,530 shares during the period. Finally, Citadel Advisors LLC bought a new position in shares of Ascentage Pharma Group International during the third quarter valued at approximately $383,000.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.